DRKS00025129招募中不适用
Transthyretin amyloidosis (ATTR) in TAVR patients - establishment of a multicenter register (TAP-TAVI register) - TAP-TAVI Register
niklinik Köln, Kardiologie0 个研究点目标入组 600 人开始时间: 2021年6月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 65 Years 至 one（—）
- 性别
- All
入选标准
- •Patients at age of 65 years and older with myocardial hypertrophy (interventricular septum thickness of 12 mm and more) with are undergoing TAVR for aortic valve stenosis. Every patient must agress to the information and consent of the study.
排除标准
- •Patients who do not agree to the information and consent of the study, patients who are currently in panel system and patients who do not meet the inclusion criteria can not be enrolled. Also patients who do not agree to undergo further diagnostics (if indicated) can not bei enrolled.
研究者
相似试验
招募中
3 期
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantTransthyretin AmyloidosisAmyloidosisNCT06563895Eidos Therapeutics, a BridgeBio company587
招募中
不适用
ATTR amyloidosis in patients undergoing transcatheter aortic valve replacement: from prevalence to hemodynamic consequence.AmyloidosisNL-OMON55157niversitair Medisch Centrum Groningen340
已完成
不适用
Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.Hereditary Transthyretin Amyloidosis (ATTRv)PolyneuropathyNCT05560555Pfizer5
进行中（未招募）
不适用
The purpose of this substudy is to describe the collection of bloodsamples to be used for development and validation of a biomarker assay.EUCTR2013-004090-28-ITFold RX Pharmaceuticals, a Pfizer Company45
招募中
不适用
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEFHeart Failure, DiastolicTransthyretin AmyloidosisAmyloidosisHeart FailureNCT05577819Massachusetts General Hospital515